Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$13.15 USD

13.15
108,198

-0.35 (-2.59%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $13.12 -0.03 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ENTA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Enanta Pharmaceuticals, Inc. [ENTA]

Reports for Purchase

Showing records 1 - 20 ( 163 total )

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

02/08/2024

Company Report

Pages: 7

FY1Q24 Recap; Approaching Key Quarter in 3Q24 With at Least Two Data Readouts From Its RSV Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

01/05/2024

Daily Note

Pages: 5

RSV Program Top-line Readouts On Target in 3Q24; Enanta Reveals New Immunology Program; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for ENTA 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

11/21/2023

Company Report

Pages: 7

FY4Q23 Recap; EDP-323 RSV Challenge Study Initiated; 3Q24 Readouts to Inform RSV Program''s Path Forward; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

10/23/2023

Company Report

Pages: 8

Taking a Deep Dive On The Significant Unmet Need in RSV; Reduce PT to $30 Following Model Updates

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

09/19/2023

Daily Note

Pages: 5

EDP-323 Data Presentation at ESWI Influenza Conference Sets the Stage For Phase 2 Challenge Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

08/08/2023

Company Report

Pages: 8

F3Q23 Recap; EDP-323 Advances Into RSV Challenge Study in Early 4Q23; First Data Expected in 2Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

06/21/2023

Company Report

Pages: 8

Phase 1 Dataset Supports EDP-323''s Advancement Into Human Challenge Study For RSV by Early 4Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

05/09/2023

Company Report

Pages: 9

FY2Q23 Recap; EDP-235 Improved Symptoms But No Virologic Effect Observed; EDP-323 Data Expected in June; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

03/16/2023

Industry Report

Pages: 6

ICAR 2023: Two Presentations in Our Coverage Universe Provide Early Datasets in COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

02/08/2023

Company Report

Pages: 7

FY1Q23 Recap; SPRINT Data Expected in May; Positive Results to Support Phase 3 in 2H23; Raising PT to $68; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

01/09/2023

Daily Note

Pages: 4

Two Data Readouts From COVID-19 and RSV Programs in 1H23; New Research Programs Expand Pipeline; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

12/09/2022

Company Report

Pages: 48

Looking for a Second Act; We See Value in the RSV Program; Initiate Buy, $56 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 50.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

06/03/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

06/02/2022

Company Report

Pages: 8

Paxlovid Rebound Theory & EDP-235

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

05/19/2022

Company Report

Pages: 6

RSV Study Hints Again at Efficacy, but Misses Primary Endpoint

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

05/19/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

05/12/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

05/11/2022

Company Report

Pages: 7

FY2Q22 Update - Strong Cash & Catalysts, but Lowering PT to $70 PT

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party